{"DataElement":{"publicId":"3014963","version":"1","preferredName":"Patient Clinical Study Agent Hypersensitivity Personal Medical History Ind-2","preferredDefinition":"the yes/no indicator related to a patient's hypersensitivity to an agent used in the clinical study.","longName":"3014961v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3014961","version":"1","preferredName":"Patient Clinical Study Agent Hypersensitivity Personal Medical History","preferredDefinition":"information related to patient's personal medical history including hypersensitivity to an agent used in the clinical study.","longName":"2233604v1.0:3014959v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3014959","version":"1","preferredName":"Clinical Study Agent Hypersensitivity Personal Medical History","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):An exaggerated response by the immune system to a drug or other substance.:an account of all medical events and problems a person has experienced.","longName":"C15206:C1708:C3114 :C18772","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hypersensitivity","conceptCode":"Hypersensitivity","definition":"An exaggerated response by the immune system to a drug or other substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80497F89-0AAD-7A48-E040-BB89AD4327BD","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"ONEDATA","dateModified":"2010-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"80494550-55AF-13EF-E040-BB89AD4362B1","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"},{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"4104890","version":"1","longName":"GOG-0229L","context":"NRG"},{"publicId":"10000430","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"10000429","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"4104905","version":"1","longName":"GOG-0186I","context":"NRG"},{"publicId":"4104891","version":"1","longName":"GOG-0229N","context":"NRG"},{"publicId":"4104916","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000500","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000499","version":"1","longName":"GOG-0257","context":"NRG"}]}],"AlternateNames":[{"name":"3014961v1.0:2018257v1.0","type":"USED_BY","context":"CTEP"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"},{"name":"KnHysenIAgt","type":"COG GDE Short Name","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"3014961v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"3014961v1.0:2018257v1.0","type":"USED_BY","context":"OHSU Knight"},{"name":"PT_CL_STUD_AGT_HYPERSE","type":"Context Short Name","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"PtHysenExptSdyDgInd","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"Known hypersensitivity to any","type":"Preferred Question Text","description":"Known hypersensitivity to any of the components of vorinostat or other agents used in the study","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Known hypersensitivity to any of the components of 5-fluorouracil/leucovorin, capecitabine, oxaliplatin, or bevacizumab","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity reaction to any of the study drugs or excipients, e.g. polysorbate 80 and Cremophor EL?","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Has the patient experienced a previous serious hypersensitivity reaction to any of the agents the patient will receive as part of the C-11 trial?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Does the patient have known sensitivity to any of the products to be administered during dosing?","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Known allergy to gadolinium","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Is the patient known to be hypersensitive to aprepitant, granisetron or any kind of the components of the patch or to dexamethasone?","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to any components of fosbretabulin tromethamine or bevacizumab?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Known hypersensitivity to any of the components of dasatinib or bevacizumab","url":null,"context":"CTEP"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Does the patient have a history of severe (NCI-CTCAE v. 4.0 greater than or equal to grade 3) allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients (10 mM Tris buffered saline) in the investigational agent?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Does patient have a known hypersensitivity to E.coli-derived proteins, Filgrastim, or any component of Filgrastim","url":null,"context":"CTEP"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Does the patient have a history of hypersensitivity reaction to drugs formulated with polysorbate 80?","url":null,"context":"CTEP"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Does the patient have known allergies to ALC (acetyl-L-carnitine)?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_2","type":"Alternate Question Text","description":"Does the patient have a history of allergic reaction to irinotecan","url":null,"context":"CTEP"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Does the patient have a history of severe (NCI-CTCAE v. 4.0 greater than or equal to grade 3) allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or Tris buffered saline?","url":null,"context":"CTEP"},{"name":"OHSU Text 1","type":"Alternate Question Text","description":"Is subject sensitive to drug in panel?","url":null,"context":"OHSU Knight"},{"name":"COG_CRF_Text_3","type":"Alternate Question Text","description":"Does patient have GM-CSF hypersensitivity?","url":null,"context":"CTEP"},{"name":"CRF Text  12","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity reaction to any of the study drugs or excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl alcohol","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_4","type":"Alternate Question Text","description":"Does patient have hypersensitivity to excipients of the study drug","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Does patient have known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)?","url":null,"context":"COG"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity reactions attributed to buparlisib or to its excipients?","url":null,"context":"PBTC"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"Does patient have known sensitivity to any of the products to be administered during the study?","url":null,"context":"COG"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"Has patient had prior allergy to daunorubicin, cytarabine or liposomal lipids?","url":null,"context":"CTEP"},{"name":"NRG CRF_Text15","type":"Alternate Question Text","description":"Does patient have known allergy to any component of the study treatment formulations?","url":null,"context":"NRG"},{"name":"CRF_Text_12","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text16","type":"Alternate Question Text","description":"Allergy to bupropion","url":null,"context":"NRG"},{"name":"COG CRF Text 15","type":"Alternate Question Text","description":"Has patient had prior allergy to daunorubicin and/or cytarabine?","url":null,"context":"COG"},{"name":"COG CRF Text 17","type":"Alternate Question Text","description":"Does the patient have any known hypersensitivity or contraindication to the components of the study drug?","url":null,"context":"COG"},{"name":"COG_CRF_TEXT_18","type":"Alternate Question Text","description":"Does patient have allergic reaction to indicated agents?","url":null,"context":"COG"},{"name":"COG_CRF_TEXT_19","type":"Alternate Question Text","description":"Does patient have allergic reaction to indicated agents","url":null,"context":"COG"},{"name":"COG_CRF_TEXT_20","type":"Alternate Question Text","description":"Does patient have hypersensitivity to indicated agents","url":null,"context":"COG"},{"name":"CRF Text 18","type":"Alternate Question Text","description":"Dose the patient have known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor® EL)?","url":null,"context":"CTEP"},{"name":"CRF Text13","type":"Alternate Question Text","description":"is patient proteasome inhibitor sensitive?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Does the patient have a history of a severe hypersensitivity reaction to monoclonal antibody or pembrolizumab and/or its excipients?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biological composition to olaparib or tremeliumumab?","url":null,"context":"NRG"},{"name":"ABTC 1802 Text 1","type":"Alternate Question Text","description":"Does the patient have a known hypersensitivity or contraindication to any component of any of the study drugs?","url":null,"context":"ABTC"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Does patient have a history of hypersensitivity to dabrafenib, trametinib, HCQ or any other excipients or compounds of a similar chemical or biologic composition?","url":null,"context":"PBTC"},{"name":"CRF Text 22","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions to CT contrast, iodine or shellfish?","url":null,"context":"CTEP"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Does patient have hypersensitivity to excipients of the study drug?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Does the patient have a history of a severe hypersensitivity reaction to monoclonal antibody or MK-3475 pembrolizumab and/or its excipients?","url":null,"context":"NRG"},{"name":"COG CRF TEXT 02","type":"Alternate Question Text","description":"Does patient have known hypersensitivity to any of the components of LOXO-292?","url":null,"context":"COG"},{"name":"CRF Text 23","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biological composition to durvalumab, olaparib, or cediranib?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Dose the patient have known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor® EL, polysorbate 80)?","url":null,"context":"NRG"},{"name":"CRF Text24","type":"Alternate Question Text","description":"Hypersensitivity to immunotherapy and/or any of its excipients.","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipatasertib, paclitaxel or carboplatin?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text17","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and/or ipilimumab including severe hypersensitivity reactions to any monoclonal antibody?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_5","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, copanlisib, or other agents used in this study?","url":null,"context":"NRG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to any component of tiragolumab or atezolizumab injection?","url":null,"context":"COG"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or tiragolumab formulation?","url":null,"context":"COG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Does the patient have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or M1774 used in study?","url":null,"context":"NRG"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Does the patient have known hypersensitivity to the study drugs or their ingredients?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_6","type":"Alternate Question Text","description":"Does the patient have history of allergic reaction to the study agents, compound of similar chemical or biologic composition of the study agents or any of their excipients?","url":null,"context":"NRG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"80494550-55C1-13EF-E040-BB89AD4362B1","latestVersionIndicator":"Yes","beginDate":"2010-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-02-23","modifiedBy":"TYRRELLM","dateModified":"2023-10-23","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"10.23.2023 Added AQT per ticket request CADSR0002989_mmt","unresolvedIssues":null,"deletedIndicator":"No"}}